ImmunityBio Names Enrique Diloné as Chief Technology Officer
Retrieved on:
Thursday, August 3, 2023
Biotechnology, General Health, Health, Pharmaceutical, Oncology, Vaccine, OSI Pharmaceuticals, Therapy, Doctor of Philosophy, CMC, Bachelor of Arts, Licensure, Bladder cancer, Congenital muscular dystrophy, Chemistry, Patient, Harvard Business School, Eyetech, Quality control, Growth, Amicus Therapeutics, FDA, Seton Hall University, Pharmaceutical industry, New York University, ImmunityBio COVID-19 vaccine
ImmunityBio, Inc. ( NASDAQ: IBRX ), a clinical-stage immunotherapy company, today announced that it has named Enrique Diloné, Ph.D., to the newly created role of Chief Technology Officer.
Key Points:
- ImmunityBio, Inc. ( NASDAQ: IBRX ), a clinical-stage immunotherapy company, today announced that it has named Enrique Diloné, Ph.D., to the newly created role of Chief Technology Officer.
- Diloné’s career spans more than 30 years of chemistry, manufacturing and controls (CMC) management, pharmaceutical supply chain management, and regulatory responsibilities.
- “Enrique will play a critical role in helping us manage future growth through best-in-class manufacturing processes and supply chain and quality assurance processes that are second to none.”
Prior to joining ImmunityBio, Diloné served as Chief Technology Officer of Prothelia, a privately held biotech company developing treatments for patients with congenital muscular dystrophy. - Diloné will initially work closely with Dr. Lennie Sender, who had been overseeing manufacturing as part of his role as Chief Operating Officer (COO).